I’ve already read on the socials some whinging that the big end of town are coming in a snatching all the hard work from the existing players in the market.
That may be so but I’d suggest the reputation and professionalism of the Boots approach is already coming through.
Below you’ll see the questions that CLR sent through requesting further information about the set up at SureLeaf.
Within hours I’ve head clear concise answers.
In ten years of sending out requests to cannabis companies of all ilks around the world this is the first time CLR has received a response with this level of professionalism.
Boots, of course, have a reputation to uphold and it behoves them to act responsibly unlike a number of “medical” cannabis companies i could name around the world.
I suggest to Sureleaf & Boots management that once they get this up and running in the UK there’s a wide open market in Australia and other jurisdictions looking for this type of approach based on commonsense , education and professionalism. I also hope that they don’t play the US game of entering into internecine politicking in relation to hemp products and adult use cannabis when those conversations appear. Staying in the lane and providing a professional medical cannabis service to the wider population should serve them very well in the long term
CLR Asked
Dear Press office
Thankyou for the update on the new service by Boots
I would just like to clarify a few details for reporting
A) Could you please give more details on the prescriptions process – the prescribing doctors are they GP’s outside the Boots infrastructure or are they doctors employed directly by boots to provide tele services to patients?
B) If the latter how are these doctors employed to work for the boots cannabis dispensing service and are they full time or just contracted to work specific hours a week?
C) Can you provide any details about the UK medical cannabis supplier
i) What is the name of the company?
ii) Are they owned or contracted by Boots or a Boots related entity?
D) What cannabis products do they supply
i) Flower? If so what strains?
ii) Edibles?
iii) Tinctures?
iv) Vapes?
E) The press release says prescriptions cost £40 – are you able to provide more detail on this pricing structure and what people are paying for – is it the telehealth charge + the prescription. If not what is the telehealth consultation charging structure? and what is the prescription charge?
F) How many times can a patient apply to receive medical cannabis in a given time frame?
G) The press release says that the cannabis is produced in a Carbon Neutral environment . Are you able to provide any more details as to the veracity of this claim?
H) Boots is owned by Canadian company Whittington Investments who also have a stake in Shoppers Drug Mart who supply prescription cannabis in Canada. Can you confirm that there are no links in the supply chain between the UK and Canada?
I very much look forward to hearing from you
Yours sincerely
Sean Hocking
Editor – Cannabis Law Report
The Response
Please see our press release here:
In terms of your other questions, please see answers in order below.
A) As per our press release:
SureLeaf brings together specialist consultants, multidisciplinary clinical oversight and ongoing patient monitoring throughout treatment. Patients aged 25 or over with an eligible condition can begin their assessment online, with suitability reviewed by the clinical team before progressing to a video consultation with a consultant in the relevant medical specialty who is on the General Medical Council Specialist Register.
Any proposed prescription will be independently reviewed by a multidisciplinary clinical team that includes a second, independent consultant, before treatment begins. Patients must have previously tried conventional treatments without achieving adequate symptom relief.
B) SureLeaf is operated by Boots Online Doctor, with prescribing decisions made by specialist consultants within the service’s clinical governance framework.
C) SureLeaf works with UK-based medical cannabis supplier Glass Pharms, an external supplier which supplies the products available through the service.
D) SureLeaf offers a deliberately limited range of medical cannabis oils and flower products, with the specific product, formulation and dose determined according to the patient’s individual clinical need.
E) SureLeaf offers an initial £89 trial plan, which includes the first specialist consultation and an initial medical cannabis oil prescription where clinically appropriate. Patients can then choose an annual subscription costing £99, covering ongoing clinical care and reviews. Patients who have previously used medical cannabis can also access the annual plan directly.Medication is charged separately after the initial treatment period, with oils starting from £35 for 10ml and flower products from £38 for 5g. Costs vary depending on the product and quantity prescribed
F) Prescriptions are issued according to the patient’s individual clinical needs and are subject to ongoing clinical review. Each prescription provides up to 28 days’ treatment, with patients required to complete a clinical questionnaire before repeat prescriptions are issued.Patients also undergo an initial review after 28 days, followed by reviews at least every three months.
G) Our press release does not make this claim. Any questions about Glass Pharms’ cultivation processes or environmental credentials would be best directed to them.
H) SureLeaf’s medical cannabis products are sourced through our UK supplier, Glass Pharms.
Best
Press Office Manager
Full Text Press Release
Boots Online Doctor launches new specialist medical cannabis service to support patients living with long-term health conditions
16 November 2026
News Healthcare
- Boots Online Doctor launches SureLeaf, a specialist doctor-led medical cannabis service for people living with eligible chronic pain conditions, generalised anxiety disorder or insomnia
- The service offers eligible patients another treatment option where conventional treatments have not provided adequate symptom relief, supported by specialist clinical assessment and care
- To help strengthen the real-world evidence for medical cannabis, Boots is exploring a collaborative research programme with the University of Nottingham examining patient outcomes, prescribing practices and experience in the treatment of chronic pain
Boots Online Doctor today announces the launch of SureLeaf, a specialist medical cannabis service giving eligible patients living with chronic pain, generalised anxiety disorder or insomnia access to consultant-led assessment, treatment and ongoing clinical care.
The new service expands the range of specialist healthcare available through Boots Online Doctor, giving eligible patients another treatment option to consider and greater access to clinical expertise.
Jamie Kerruish, Chief Healthcare Officer, Boots, said: “At Boots, we’re committed to making healthcare more accessible and helping people find the right support for their individual needs. Millions of people live with ongoing pain and for some, conventional treatments do not provide adequate symptom relief. This can have a significant impact on everyday life, from working and sleeping well to spending time with family and doing the things they enjoy. Medical cannabis is a specialist area of healthcare and, through SureLeaf, we’re giving eligible patients another treatment option to consider, supported by clinical expertise and robust ongoing care. Ultimately, it’s about helping people explore appropriate options that could help them better manage their symptoms and improve their quality of life.”
SureLeaf brings together specialist consultants, multidisciplinary clinical oversight and ongoing patient monitoring throughout treatment. Patients aged 25 or over with an eligible condition can begin their assessment online, with suitability reviewed by the clinical team before progressing to a video consultation with a consultant in the relevant medical specialty who is on the General Medical Council Specialist Register.
Any proposed prescription will be independently reviewed by a multidisciplinary clinical team that includes a second, independent consultant, before treatment begins. Patients must have previously tried conventional treatments without achieving adequate symptom relief.
Once treatment begins, patients will receive ongoing clinical support and monitoring, including an initial review after 28 days followed by reviews at least every three months. Validated questionnaires will be used throughout treatment to assess relevant areas including quality of life, pain, anxiety, sleep and mood, helping clinicians monitor the effectiveness of treatment.
Dr David Gwynne, Medical Director, Boots Online Doctor, said: “Medical cannabis is not appropriate for everyone and prescribing decisions need to be made carefully on an individual patient basis. SureLeaf has therefore been designed with strong clinical safeguards and specialist oversight at every stage, so treatment is only considered for patients where it is clinically appropriate. Our priority is to ensure patients receive responsible, clinically led care, from their initial specialist assessment through to ongoing monitoring and review once treatment begins.”
Alongside the launch, Boots and the University of Nottingham are exploring a collaborative research programme to build on the existing real-world evidence and understanding of medical cannabis in chronic pain management.
The work would build on the existing partnership between the two organisations, which is based on a shared commitment to improve patient care through evidence led innovation and aims to help inform future clinical practice, support responsible service development and contribute to the broader understanding of the role medical cannabis could play.
SureLeaf will operate as a private healthcare service through Boots Online Doctor and will support people living with the following eligible conditions:
- Chronic pain conditions including chronic primary and neuropathic pain, fibromyalgia, complex regional pain syndrome, chronic back or neck pain, osteoarthritis, rheumatoid arthritis, sciatica, peripheral neuropathy, trigeminal neuralgia, phantom limb pain, chronic migraine, endometriosis-related pelvic pain and chronic abdominal or pancreatic pain
- Generalised anxiety disorder
Further information, including full eligibility criteria and how to access the service, is available on the dedicated service page here.
Who are Glass Pharms?
Boots appear to have thought wisely about who they deal with in terms of supply.
The MD has a GW Pharma background, the CFO has a background in UK high street including M&S, Blackwells & Tesco and you’ll see similar CV’s spread throughout the management team.
I’d suggest the Canadian owners have been smart here and realised that it’s best to let the Brits get on with it without North American interference.
The likes of Curaleaf et al might just be finding that their well laid European plans might just have a worthy competitor to deal with.
If Burnham was being smart about cannabis and Europe it”s this type of business arrangement that would make a good sell into Europe as to how medical cannabis might be done on a larger scale. God know the French & the Germans need to learn how to make things work properly.
This set up looks from the outset to be the antithesis of the “Talman Group” approach. Very British, quiet and efficient and the possibility of a model that could be exported.
Rarely do i have days when I think capital can work wisely with cannabis. Let’s hope that this is as positive as it promises to be.

















